EGFR mutations and EML4-ALK translocations in elderly patients with NSCLC
What is it about?
Very elderly patients with non-squamous NSCLC show high rates of driver alterations in EGFR and ALK
Why is it important?
Testing for EGFR and ALK alterations should not be restricted to younger patients, as they often are not suitable for cytotoxic therapy and may benefit from targeted treatments.
The following have contributed to this page: Professor Rudolf M. Huber